Department of Radiation Oncology, Jiangxi Cancer Hospital, Nanchang, China.
Cancer. 2013 Sep 1;119(17):3170-6. doi: 10.1002/cncr.28201. Epub 2013 Jun 13.
This study sought to compare the clinical outcomes of upper versus whole-neck prophylactic irradiation in the treatment of patients with node-negative nasopharyngeal carcinoma (NPC).
Between November 2005 and June 2012, 301 patients with node-negative NPC were randomly assigned to receive primary plus prophylactic upper neck irradiation (UNI, 153 patients) or primary plus whole-neck irradiation (WNI, 148 patients). Patients in both groups received irradiation to the primary tumor and the upper neck nodal regions, and patients in the WNI group also received irradiation to the lower neck. The main endpoint of the study was to compare the lower neck control rate between the 2 groups.
With a median follow-up period of 39 months (range, 6-84 months), no patient in either group had a cervical node relapse. The overall survival at 3 years was 89.5% (95% confidence interval [CI] = 84.1%-95.0%) in the UNI group and 87.4% (95% CI = 81.4%-93.5%) in the WNI group (hazard ratio [HR] = 0.866, 95% CI = 0.41-1.82; P = .70). The 3-year relapse-free survival rate was 89.8% and 89.3% (95% CI = 84.2%-95.3% and 83.7%-94.8%, HR = 0.914, 95% CI = 0.42-2.00; P = .82), and the 3-year metastasis-free survival rate was 91.7% and 90.9% (95% CI = 87.0%-96.5% and 85.7%-96.1%) for the UNI and WNI groups, respectively (HR = 1.007, 95% CI = 0.44-2.32; P = .99).
Prophylactic upper neck irradiation is sufficient for patients with node-negative NPC.
本研究旨在比较局部预防性上颈部照射与全颈部预防性照射治疗无颈部淋巴结转移的鼻咽癌(NPC)患者的临床结局。
2005 年 11 月至 2012 年 6 月,301 例无颈部淋巴结转移的 NPC 患者被随机分为两组,分别接受原发灶加预防性上颈部照射(UNI 组,153 例)或原发灶加全颈部照射(WNI 组,148 例)。两组患者均接受原发灶和上颈部区域的照射,WNI 组患者还接受下颈部照射。本研究的主要终点是比较两组患者的下颈部控制率。
中位随访时间为 39 个月(范围 6-84 个月),两组患者均无颈淋巴结复发。UNI 组 3 年总生存率为 89.5%(95%置信区间[CI]:84.1%-95.0%),WNI 组为 87.4%(95% CI:81.4%-93.5%)(风险比[HR]:0.866,95% CI:0.41-1.82;P=0.70)。3 年无复发生存率分别为 89.8%和 89.3%(95% CI:84.2%-95.3%和 83.7%-94.8%,HR:0.914,95% CI:0.42-2.00;P=0.82),3 年无远处转移生存率分别为 91.7%和 90.9%(95% CI:87.0%-96.5%和 85.7%-96.1%)(HR:1.007,95% CI:0.44-2.32;P=0.99)。
对于无颈部淋巴结转移的 NPC 患者,预防性上颈部照射是足够的。